Sign in Subscribe
Pharmaceutical industry

Inovio Pharmaceuticals Expands Scientific Advisory Board with Renowned Experts

Strategic Insights

— 2 min read

Inovio Pharmaceuticals has expanded its scientific advisory board with the appointment of two prominent leaders in the fields of vaccines and cancer immunotherapeutics. Dr. Thomas S. Edgington, Emeritus Professor of the Scripps Research Institute, and Dr. Philip D. Greenberg, Professor of Medicine (Oncology) and Immunology at the University of Washington, have joined the board to guide Inovio's DNA vaccine technology into advanced clinical stages. The addition of these experts brings the company's total advisory board members to five, including Dr. David B. Weiner, often referred to as the "Father of DNA Vaccines."

Dr. Thomas S. Edgington has over 500 publications in the biomedical sciences and filed over 25 patents. He has served as president and a board member of the Federation of American Societies for Experimental Biology (FASEB) and has founded several biotechnology companies, including Corvas International, Inc. Dr. Edgington said, "Inovio's DNA vaccine technology has displayed in humans the ability to induce immune responses, including T cell responses that are vital to therapeutic vaccines, which are equivalent to live virus vaccines and superior to other non-live vaccine platforms."

Key Takeaways:

  • Inovio Pharmaceuticals has expanded its scientific advisory board with the appointment of Dr. Thomas S. Edgington and Dr. Philip D. Greenberg.
  • The addition of Dr. Edgington and Dr. Greenberg brings the company's total advisory board members to five, including Dr. David B. Weiner.
  • Dr. Edgington has over 500 publications in the biomedical sciences and filed over 25 patents.
  • Dr. Edgington has served as president and a board member of the Federation of American Societies for Experimental Biology (FASEB) and has founded several biotechnology companies.
  • Dr. Edgington believes that Inovio's DNA vaccine technology has the potential to provide profound medical benefits.
  • Dr. Greenberg is Professor of Medicine (Oncology) and Immunology at the University of Washington and heads the Program in Immunology at the Fred Hutchinson Cancer Research Center.
  • Dr. Greenberg's research includes studies in transgenic mice to elucidate the requirements for inducing therapeutically effective T-cell responses to self-proteins that are overexpressed in tumors.

Statistics:

  • Dr. Edgington has over 25 patents filed.
  • Dr. Edgington has over 500 publications in the biomedical sciences.
  • Inovio has five members on its scientific advisory board, including Dr. Edgington, Dr. Greenberg, and Dr. David B. Weiner.
  • Inovio is developing a new generation of vaccines, called DNA vaccines, to treat and prevent cancers and infectious diseases.
  • Inovio's SynCon vaccines are designed to provide broad cross-strain protection against known as well as newly emergent unmatched strains of pathogens such as influenza.

Sources:

  • PR Newswire, "Inovio Pharmaceuticals Appoints Two Prominent Experts to Scientific Advisory Board" (September 6, 2011)
  • Inovio Pharmaceuticals, Inc. Press Release, "Inovio Pharmaceuticals Appoints Two Prominent Experts to Scientific Advisory Board" (September 6, 2011)

Read more